Letter to the Editor
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2021; 27(48): 8370-8373
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8370
Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19
Ken Sato, Yuichi Yamazaki, Toshio Uraoka
Ken Sato, Yuichi Yamazaki, Toshio Uraoka, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Gunma, Japan
Author contributions: Sato K designed the research and drafted the article; Yamazaki Y and Uraoka T analyzed the data and gave critical advice; and Sato K revised the letter and performed the final approval of the version of the article to be published.
Conflict-of-interest statement: We received no financial support for this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ken Sato, MD, PhD, Associate Professor, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan. satoken@gunma-u.ac.jp
Received: July 29, 2021
Peer-review started: July 29, 2021
First decision: November 7, 2021
Revised: November 18, 2021
Accepted: November 10, 2021
Article in press: December 10, 2021
Published online: December 28, 2021
Processing time: 148 Days and 0.4 Hours
Core Tip

Core Tip: To cope with dysregulation of liver function in coronavirus disease 2019 (COVID-19), drug-induced liver injury (DILI) due to investigational treatments/drugs or drug-drug or drug-disease interactions should be considered. We described useful information associated with clinical practice. We discussed the potential hepatotoxicity of dexamethasone or remdesivir as representative investigational treatments/drugs for COVID-19. These drugs are predicted to be used for a certain time in monotherapy or combination therapy. We also reported glycyrrhizic acid and ursodeoxycholic acid as therapeutic candidates for the control of DILI due to investigational treatments/drugs, as well as COVID-19.